A Novel Self‐Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations
Advanced Science · 2024-11 · 11 (43)
DOI: 10.1002/advs.202402936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 23.09.2024. Verfasst von Yue Gong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Virogin Biotech Co. Ltd, Jiading District, Shanghai, 200000, China. Hauptthemen laut MEDLINE: Mutation, RNA, Messenger, SARS-CoV-2. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The efficacy and safety of self‐amplifying mRNA (saRNA) have been demonstrated in COVID‐19 vaccine applications. Unlike conventional non‐replicating mRNA (nrmRNA), saRNA offers a key advantage: its self‐replication mechanism fosters efficient expression of the encoded protein, leading to substantial dose savings during administration. Consequently, there is a growing interest in further optimizing the expression efficiency of saRNA. In this study, in vitro adaptive passaging of saRNA is conducted under exogenous interferon pressure, which revealed several mutations in the nonstructural protein (NSP). Notably, two stable mutations, Q48P and I113F, situated in the NSP3 macrodomain (MD), attenuated its mono adenosine diphosphate ribose (MAR) hydrolysis activity and exhibited decreased replication but increased payload expression compared to wild‐type saRNA (wt saRNA). Transcriptome sequencing analysis unveils diminished activation of the double‐stranded RNA (dsRNA) sensor and, consequently, a significantly reduced innate immune response compared to wt saRNA. Furthermore, the mutant saRNA demonstrated less translation inhibition and cell apoptosis than wt saRNA, culminating in higher protein expression both in vitro and in vivo. These findings underscore the potential of reducing saRNA replication‐dependent dsRNA‐induced innate immune responses through genetic modification as a valuable strategy for optimizing saRNA, enhancing payload translation efficiency, and mitigating saRNA cytotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Virogin Biotech Co. Ltd, Jiading District, Shanghai, 200000, China.
- Virogin Biotech Canada Ltd, Vancouver, BC, V6V 3A4, Canada.
ORCID-Profile: Yue Gong, William Jia
Zitieren
APA
Gong, Y., Yong, D., Liu, G., Xu, J., Ding, J., & Jia, W. (2024). A Novel Self‐Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations. Advanced Science, 11(43). https://doi.org/10.1002/advs.202402936
Vancouver
Gong Y, Yong D, Liu G, Xu J, Ding J, Jia W. A Novel Self‐Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations. Advanced Science. 2024;11(43). doi:10.1002/advs.202402936
BibTeX
@article{Gong2024,
author = {Gong, Yue and Yong, Danni and Liu, Gensheng and Xu, Jiang and Ding, Jun and Jia, William},
title = {A Novel Self‐Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {43},
doi = {10.1002/advs.202402936}
}
EUVIMED